Stock AMEU.F ANTERIS TECHNOLOGIES LTD
Add to a list
To use this feature you must be a member
Log inSign up

Anteris Technologies Ltd Stock OTC Markets

Equities

AMEU.F

AU0000088841

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets
Other stock markets
 11:52:55 2024-05-10 am EDT 		5-day change 1st Jan Change
14.36 USD -2.31% Intraday chart for Anteris Technologies Ltd -2.31% +8.79%
Apr. 18 Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31 MT
Apr. 10 Anteris Technologies Raises AU$23 Million for DurAVR Study MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 6M 3.96M Sales 2025 * 6M 3.96M Capitalization 404M 267M
Net income 2024 * -79M -52.15M Net income 2025 * -85M -56.11M EV / Sales 2024 * 63.2 x
Net cash position 2024 * 25M 16.5M Net cash position 2025 * 25M 16.5M EV / Sales 2025 * 63.2 x
P/E ratio 2024 *
-5.66 x
P/E ratio 2025 *
-6.01 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.75%
More Fundamentals * Assessed data

Chart Anteris Technologies Ltd

Dynamic Chart

Latest news about Anteris Technologies Ltd

Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31 MT
Anteris Technologies Raises AU$23 Million for DurAVR Study MT
Anteris Declares Upbeat Results from Human Trials of Heart Valve MT
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Anteris Technologies Completes Enrollment for Heart Valve Device Study MT
Anteris Technologies Secures AU$1 Million Tax Rebate for 2022 MT
Anteris Technologies Ltd(ASX:AVR) dropped from S&P Global BMI Index CI
Anteris Technologies Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case CI
Montefiore Enrolls Patients for US Early Feasibility Study for Anteris Technologies' DurAVR THV MT
Anteris Technologies Announces First Successful Implantation of Duravr? Thv in A Valve-In-Valve Procedure CI
Anteris Technologies Implants DurAVR THV in Valve-in-Valve Procedure; Shares Jump 3% MT
Anteris Technologies Validates Efficacy of Aortic Valve Device MT
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4% MT
Anteris Technologies, v2vmedtech to Develop Heart Valve Repair Device MT
More news

Press releases Anteris Technologies Ltd

Anteris talks market superiority of its biomimetic TAVR valve AQ
Anteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023 BU
Anteris Technologies Ltd - DurAVR Demonstrates Exceptional Results in Second Valve-in-Valve Case AQ
DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case BU
Anteris Technologies Ltd - Montefiore Health System Enrolls Patients in the US Early Feasibility Study AQ
More press releases

Quotes and Performance

1 day-2.31%
1 week-2.31%
Current month-2.31%
1 month-7.53%
3 months+28.79%
6 months+14.88%
Current year+8.79%
More quotes

Highs and lows

1 week
14.36
Extreme 14.36
14.36
1 month
14.36
Extreme 14.36
14.70
Current year
10.50
Extreme 10.5
15.53
1 year
10.50
Extreme 10.5
15.80
3 years
5.74
Extreme 5.74
20.50
5 years
0.00
Extreme 0
20.50
10 years
0.00
Extreme 0
20.50
More quotes

Managers and Directors - Anteris Technologies Ltd

Managers TitleAgeSince
Wayne Paterson CEO
 Chief Executive Officer 56 14-10-09
Matthew McDonnell DFI
 Director of Finance/CFO - 18-11-22
Chris Meduri CTO
 Chief Tech/Sci/R&D Officer - 21-09-05
Members of the board TitleAgeSince
John Seaberg CHM
 Chairman 72 14-10-09
Stephen Denaro BRD
 Director/Board Member - 18-10-30
Wayne Paterson CEO
 Chief Executive Officer 56 14-10-09
More insiders

Quotes

Date Price Change Volume

Delayed Quote OTC Markets, May 10, 2024 at 11:52 am EDT

More quotes

Company Profile

Anteris Technologies Ltd is an Australia-based company that is engaged in the research and development (R&D) of its structural heart products. The Company is engaged in the manufacture and sale of ADAPT regenerative tissue products globally. It is focused on developing biomimetic transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis. ADAPT is the Company’s patented anti-calcification tissue technology. Its DurAVR THV is a three dimensional (3D) single piece valve and is a biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The Company also provides ComASUR Delivery System, a balloon expandable system with the ability to rotate valves for predictable alignment with the heart’s native commissure.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-05-28 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Anteris Technologies Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
21.05 AUD
Average target price
30 AUD
Spread / Average Target
+42.52%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.84% 182B
MEDTRONIC PLC Stock Medtronic plc
+0.56% 110B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.35% 68.11B
DEXCOM, INC. Stock DexCom, Inc.
+2.39% 50.53B
CENCORA, INC. Stock Cencora, Inc.
+9.36% 44.8B
HOYA CORPORATION Stock Hoya Corporation
+2.70% 40.7B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+3.43% 26.53B
TERUMO CORPORATION Stock Terumo Corporation
+13.67% 25.02B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-0.32% 24.96B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. AVR Stock
  4. AMEU.F Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW